Kadderum (Eltrombopag)

Eltrombopag is a thrombopoietin receptor agonist that binds to the c‑Mpl receptor on megakaryocyte precursors, activating JAK/STAT signaling and stimulating platelet production in the bone marrow.

The dosage is individualized by the prescribing clinician based on the patient’s platelet count, underlying condition, response, and tolerability, following approved labeling and clinical guidelines.

Safety in pregnancy and lactation has not been established; it is generally advised to avoid use unless the potential benefit justifies the potential risk, and decisions should be made by the treating physician.

Submit an enquiry on the product page at gnhindia.com specifying the required quantity; GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Like romiplostim, eltrombopag increases platelet counts, but Kadderum is taken orally while romiplostim is administered subcutaneously; differences in route, dosing frequency, and specific labeling allow clinicians to choose based on patient preference and clinical context.

Store at below 25 °C in the original packaging, protect from moisture and direct sunlight; keep the product out of reach of children and do not use after the expiry date.

Kadderum is taken orally, usually with a low‑fat meal or as directed by the prescriber; tablets should be swallowed whole with water and not chewed or crushed unless instructed.

Serious adverse events include thromboembolic complications, significant liver injury, bone‑marrow fibrosis, and severe allergic reactions; patients should be monitored regularly for signs of these conditions and the drug should be discontinued if they occur.

Kadderum is contraindicated in patients with known hypersensitivity to eltrombopag, active thrombotic disease, uncontrolled liver disease, and in individuals who are pregnant or breastfeeding unless the benefits outweigh risks; clinicians should assess each patient’s medical history before prescribing.